Literature DB >> 23621199

Relapse-free rate with childhood acute lymphoblastic leukemia treated under the thai national protocol.

Piangjit Tharnprisan1, Jiraporn Khiewyoo, Piporn Sripraya, Surapon Wiangnon.   

Abstract

BACKGROUND: The standard national protocol for treatment of acute lymphoblastic leukemia (ALL) in children was implemented in 2006. A systematic evaluation of the treatment outcome is needed. This study examined the relapse-free survival among childhood ALL cases treated with this protocol and related factors.
MATERIALS AND METHODS: A descriptive study was conducted in children aged between 0-15 years, newly diagnosed with ALL between March 2006 and March 2011 at Srinagarind Hospital, Department of Pediatrics, Faculty of Medicine, Khon Kaen University. The patients were treated on the basis of stratified risk as per the Thai national protocol. Data were compiled from the hospital records. The Kaplan-Meier method was used to describe relapse-free survival and the Cox proportional hazard model to investigate the associated factors.
RESULTS: Of the 103 children recruited, 86 (83.5%) achieved complete remission. The total follow-up time was 3132.5 person-months. Eighteen (20.9%) relapsed. The incidence density was 0.6 per 100 person-months (95%CI: 0.4, 0.9). The respective relapse-free rates at 1, 3 and 5 years were 93.0% (95%CI: 85.1, 96.8), 84.5% (95%CI: 74.0, 90.9) and 64.1% (95%CI: 45.6, 77.8). A factor associated with the relapse-free rate was age under 1 year (HR=6.0; 95%CI: 1.1, 33.8).
CONCLUSIONS: The rate of being relapse-free in ALL children treated under the Thai national protocol at Srinagarind Hospital was better than with former protocols; however, it is still not as good as in developed countries. Further review of the treatment approach of ALL is needed.

Entities:  

Mesh:

Year:  2013        PMID: 23621199     DOI: 10.7314/apjcp.2013.14.2.1127

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  2 in total

1.  Association of ARID5B Genetic Variants with Risk of Childhood B Cell Precursor Acute Lymphoblastic Leukaemia in Latvia

Authors:  Madara Kreile; Dmitrijs Rots; Agnese Zarina; Linda Rautiainen; Zelma Visnevska-Preciniece; Zhanna Kovalova; Linda Gailite
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27

2.  What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool.

Authors:  Rosarin Sruamsiri; Alessandra Ferrario; Dennis Ross-Degnan; Avram E Denburg; A Lindsay Frazier; Sumit Gupta; Zachary J Ward; Jennifer M Yeh; Anita Katharina Wagner
Journal:  BMJ Open       Date:  2020-10-26       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.